ATE214604T1 - Verwendung von somatostatin agonisten und antagonisten zur behandlung von augenkrankheiten - Google Patents
Verwendung von somatostatin agonisten und antagonisten zur behandlung von augenkrankheitenInfo
- Publication number
- ATE214604T1 ATE214604T1 AT98929232T AT98929232T ATE214604T1 AT E214604 T1 ATE214604 T1 AT E214604T1 AT 98929232 T AT98929232 T AT 98929232T AT 98929232 T AT98929232 T AT 98929232T AT E214604 T1 ATE214604 T1 AT E214604T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- antagonists
- eye diseases
- somatostatin receptor
- somatostatin agonists
- Prior art date
Links
- 102000005157 Somatostatin Human genes 0.000 title 1
- 108010056088 Somatostatin Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 208000030533 eye disease Diseases 0.000 title 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
- 229960000553 somatostatin Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004410 intraocular pressure Effects 0.000 abstract 2
- 208000002177 Cataract Diseases 0.000 abstract 1
- 206010010741 Conjunctivitis Diseases 0.000 abstract 1
- 208000001860 Eye Infections Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010038910 Retinitis Diseases 0.000 abstract 1
- 108050001286 Somatostatin Receptor Proteins 0.000 abstract 1
- 102000011096 Somatostatin receptor Human genes 0.000 abstract 1
- 102100023801 Somatostatin receptor type 4 Human genes 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000004614 iritis Diseases 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- NHXLMOGPVYXJNR-ULWVLGNYSA-N somatostatin receptor ligand Chemical compound C([C@H]1C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ULWVLGNYSA-N 0.000 abstract 1
- 108010064556 somatostatin receptor subtype-4 Proteins 0.000 abstract 1
- 208000025889 stromal keratitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK74797 | 1997-06-24 | ||
| US5130097P | 1997-06-30 | 1997-06-30 | |
| PCT/DK1998/000267 WO1998058646A1 (en) | 1997-06-24 | 1998-06-22 | Use of somatostatin agonists and antagonists for treating diseases related to the eye |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE214604T1 true ATE214604T1 (de) | 2002-04-15 |
Family
ID=26064570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98929232T ATE214604T1 (de) | 1997-06-24 | 1998-06-22 | Verwendung von somatostatin agonisten und antagonisten zur behandlung von augenkrankheiten |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1019050B1 (de) |
| JP (1) | JP2002515912A (de) |
| AT (1) | ATE214604T1 (de) |
| AU (1) | AU7907198A (de) |
| DE (1) | DE69804332T2 (de) |
| DK (1) | DK1019050T3 (de) |
| ES (1) | ES2174447T3 (de) |
| PT (1) | PT1019050E (de) |
| WO (1) | WO1998058646A1 (de) |
| ZA (1) | ZA985410B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2246791A1 (en) * | 1998-09-01 | 2000-03-01 | Alison Buchan | Treatment of endothelium with somatostatin analogues |
| FR2796945B1 (fr) * | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments |
| AU2001292723A1 (en) | 2000-09-20 | 2002-04-02 | Schering Corporation | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| WO2002024657A2 (en) | 2000-09-20 | 2002-03-28 | Schering Corporation | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| CA2422729A1 (en) | 2000-09-20 | 2002-06-06 | Schering Corporation | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| AU2001292730A1 (en) | 2000-09-20 | 2002-04-02 | Schering Corporation | Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists |
| WO2004039403A1 (ja) * | 2002-10-31 | 2004-05-13 | Senju Pharmaceutical Co., Ltd. | 角膜障害治療剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997043278A1 (en) * | 1996-05-14 | 1997-11-20 | Novo Nordisk A/S | Somatostatin agonists and antagonists |
| EP0937065A1 (de) * | 1996-10-31 | 1999-08-25 | Novo Nordisk A/S | Somatostatin agonisten und antagonisten mit starrer konformation |
-
1998
- 1998-06-22 EP EP98929232A patent/EP1019050B1/de not_active Expired - Lifetime
- 1998-06-22 WO PCT/DK1998/000267 patent/WO1998058646A1/en not_active Ceased
- 1998-06-22 AU AU79071/98A patent/AU7907198A/en not_active Abandoned
- 1998-06-22 JP JP50361499A patent/JP2002515912A/ja active Pending
- 1998-06-22 AT AT98929232T patent/ATE214604T1/de not_active IP Right Cessation
- 1998-06-22 PT PT98929232T patent/PT1019050E/pt unknown
- 1998-06-22 ZA ZA985410A patent/ZA985410B/xx unknown
- 1998-06-22 DK DK98929232T patent/DK1019050T3/da active
- 1998-06-22 ES ES98929232T patent/ES2174447T3/es not_active Expired - Lifetime
- 1998-06-22 DE DE69804332T patent/DE69804332T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1019050B1 (de) | 2002-03-20 |
| AU7907198A (en) | 1999-01-04 |
| WO1998058646A1 (en) | 1998-12-30 |
| PT1019050E (pt) | 2002-09-30 |
| DE69804332D1 (de) | 2002-04-25 |
| EP1019050A1 (de) | 2000-07-19 |
| DK1019050T3 (da) | 2002-07-08 |
| JP2002515912A (ja) | 2002-05-28 |
| ZA985410B (en) | 1999-01-04 |
| ES2174447T3 (es) | 2002-11-01 |
| DE69804332T2 (de) | 2002-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2470635C2 (ru) | Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза | |
| CN100417379C (zh) | 非镇静的a-2激动剂1-(2,3-二甲基-苯基)-乙基-1,3-二氢-咪唑-2-硫酮 | |
| CN1561393A (zh) | 用于治疗青光眼的糖原合成酶激酶－3(gsk－3)的抑制剂 | |
| DE60217152D1 (de) | Knochen-morphogene proteine (bmp), bmp-rezeptoren und bmp-bindungsproteine und ihre verwendung bei der diagnose und behandlung des glaukoms | |
| ATE336247T1 (de) | Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten | |
| WO2003047513A3 (en) | Method for treating ocular hypertension | |
| EA032760B1 (ru) | Соединения ингибиторы ido и tdo | |
| BRPI0408690A (pt) | composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto | |
| JP2008505173A (ja) | 痛みおよび他のα２アドレナリン作動性仲介状態を処置するための方法および組成物 | |
| ATE345794T1 (de) | Zusammensetzungen und verfahren zur behandlung von estrogenabhängigen zustanden | |
| SK7442001A3 (en) | Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds | |
| RU2370267C2 (ru) | Антагонисты cdk2 в качестве антагонистов короткой формы фактора транскрипции c-maf для лечения глаукомы | |
| KR20150013867A (ko) | 제브라피시 모델을 사용한 약물 스크리닝 방법 및 이 방법으로 스크린된 화합물 | |
| TW201643178A (zh) | 在ＭｅＢｍｔ側鏈上經雜環修飾之環孢靈素 | |
| ATE487514T1 (de) | 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom | |
| CN102105167A (zh) | 轴性近视的预防或治疗剂 | |
| PE105399A1 (es) | PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE 3a-(R)-BENCIL-2-METIL-2,3,3a,4,5,6,7-HEXAHIDRO-PIRAZOLO[4,3-c]PIRIDINA-3-ONA | |
| ATE359794T1 (de) | 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes | |
| DE69804332D1 (de) | Verwendung von somatostatin agonisten und antagonisten zur behandlung von augenkrankheiten | |
| DK1395263T3 (da) | 3, 7 eller 3 og 7 thia- eller oxaprostansyrederivater som midler til at sænke intraokulært tryk | |
| US10485786B2 (en) | Pharmaceutical composition for preventing or treating macular degeneration | |
| RU99121654A (ru) | Средства для предотвращения или лечения болезней, связанных с чрезмерной пролиферацией эпителиальных пигментных клеток сетчатки | |
| JP2015160826A (ja) | ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤 | |
| KR102876332B1 (ko) | 신경망막 질환의 치료 및/또는 예방에 치료적 활성 물질로서 사용하기 위한 화합물 | |
| US10537579B2 (en) | Rejection reaction suppressant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |